Circulating CD36 levels were positively correlated with severity of insulin resistance and atherosclerosis in several human population studies (Handberg et al., 2010; Handberg et al., 2008), and it was postulated that circulating CD36 could be used as a marker of metabolic syndromes (Koonen et al., 2011). The gene discussed is CD36; the disease is metabolic syndrome.